When the federal government shuts down, Washington D.C. doesn’t actually close — it constricts. For biotech organizations that rely on federal grants, contracts, regulatory interactions or collaborations with government-labs, a shutdown can interrupt key processes, delay milestones, create budgetary uncertainty and slow the path to market.

In this guide, we’ll walk through what types of funding may pause during a shutdown, which processes are likely to be impacted, and how companies can ramp back up once the government re-opens. Understanding what happens during a shutdown — and how to prepare for the rebound afterward — can spell the difference between a manageable delay and a months-long derailment.

What funding pauses during a government shutdown?

While not every federal funding stream freezes the moment the lights go off in Washington, many programs face interruptions or delays — and for biotech companies, the timing of that pause matters.

Ongoing contracts and awards 

In many cases, when a grant or contract has already been awarded and funds have been obligated, agencies allow the underlying work to continue during a government shutdown. Research teams can usually keep operating on previously approved budgets and timelines, provided no new approvals or funding actions are required.

However, there are important caveats:

• Reimbursements may be delayed: Even if your team keeps working, payment processing often slows or pauses until appropriations resume. That can create short-term cash-flow challenges, especially for smaller organizations or subcontractors.
• Administrative actions may be suspended: Activities such as progress report reviews, budget modifications, and approval of project changes are typically postponed until agency staff return. This can affect hiring, procurement, and compliance milestones that depend on agency sign-off.

In short, while existing research can often continue through a shutdown, the operational friction around funding and oversight can create ripple effects that last long after the government reopens.

New awards, solicitations and contract actions

One of the most immediate impacts of a government shutdown is the halt in new funding activity. Agencies stop issuing new awards, publishing solicitations, and signing new contracts until appropriations are restored.

For biotech companies, this can disrupt momentum in several ways:

• Pending opportunities stall: A promising BARDA, DoD, ARPA-H, NIH, NSF, or DOE request for proposals (RFP) may sit dormant until agency operations resume.
• Collaborations freeze midstream: Potential partnerships with federal labs or research institutions may be delayed or canceled altogether.
• Contract terms shift: Option years, milestone payments, or renewals may need to be renegotiated once work restarts, adding weeks or months to already tight development timelines.

The federal pipeline that fuels innovation and partnership pauses, not permanently, but long enough to create uncertainty for programs that depend on predictable review and award cycles.

Discretionary versus mandatory funding

Not all federal funding is affected equally during a government shutdown. The level of disruption depends on whether the funding is discretionary — subject to annual appropriations — or mandatory, meaning it continues automatically under permanent law.

Discretionary programs, which include most research grants and cooperative agreements, are far more vulnerable. When appropriations lapse, these programs simply cannot issue new awards or process pending actions. In contrast, mandatory or entitlement-based programs, such as Medicare, generally continue operating with minimal interruption.

In practice, this means that even when a department’s broader operations persist, certain divisions or research offices may pause their discretionary activities until new funding is enacted. For some agencies, existing awards remain active but oversight, review, and enforcement functions slow dramatically.

For life sciences and biotech organizations, the impact of a shutdown typically concentrates in a few key areas:

• Grant and contract continuity: Agencies such as BARDA, NIH or NSF often maintain ongoing, already-obligated awards, but they pause new peer-review cycles, new award issuances, and enrollment of new projects until funding resumes.
• Dependence on federal collaboration: Work that relies on government lab access, regulatory feedback, or joint research agreements may experience delays due to furloughed staff or closed facilities.
• Cash-flow management: Even when projects continue, reimbursement and payment processing can slow significantly. Companies should be prepared to leverage internal reserves or bridge funding strategies to maintain continuity.

In essence, discretionary programs are the lifeblood of biotech innovation — and when they pause, it’s not just a bureaucratic slowdown. It’s a test of financial planning, strategic patience, and operational agility.

What processes are impacted during a shutdown?

Beyond funding, key operational processes — especially those relevant to biotech companies — are affected when federal agencies partially shut down.

• Agency staffing and service interruptions
  When appropriations lapse, agencies invoke contingency plans. They furlough non-essential workers, limit services and suspend many activities. For instance, during recent shutdown planning, agencies signaled that scientific review meetings, new enrollments and contract actions would be delayed. (PBS) For biotech companies, the implications are: 
  • Delays in regulatory review or meetings with agencies (depending on which agency and whether it is deemed “essential”). 
  • Slowed communications — email responses, phone calls may be delayed or suspended. 
  • Contract modifications, amendments or option years may stall
    
• Grant peer-review panels, site visits, audit activities and oversight may be postponed. 
  For example, Columbia University’s research office noted that if a shutdown happens, “an overview … what to anticipate … focusing on its ramifications for federally-sponsored research” includes delays in oversight. (Columbia Research) In biotech context:
  • If you’re relying on a federal lab subcontract or a milestone tied to a government-reviewed deliverable, expect a pause. 
  • If oversight notices or audit findings cannot be addressed during the shutdown, you may accumulate backlog.
    
• Contractual obligations and compliance
  Federal contracts often require continuous compliance, reporting and deliverables. A shutdown complicates this because the government may not accept new obligations or contract modifications. As one law-firm commentary noted, “if you have a federal contract or grant … advance communication with the agency is the best preventative medicine.” (Squire Patton Boggs). Companies should proactively:
  • Review milestones tied to federal agency actions.
  • Communicate with contracting officers/grant officers about contingency plans. 
  • Document any suspension or delay caused by the shutdown for future claim or justification.
    
• Facilities, access, and collaborations
  If your biotech program depends on federal facilities (e.g., labs, instrumentation, shared resources) or collaborations with agency scientists, a shutdown may restrict access. For instance, the NSF ceased accepting reports from grantees, and federal labs shut down research axes during past shutdowns. (Wikipedia) The broader point: plan for possible access disruption.

How do companies ramp back up after a shutdown?

Once the government reopens — appropriations are passed, contingency plans lifted — there’s a transition period to resume operations. Having a ramp-up strategy helps biotech organizations get back on track quickly.

• Early actions and communication
  • Check with your agency contacts: Grant officers, contracting officers often issue guidance about resume-of-operations.
  • Confirm funding status: Ensure your award is still active, that funds are available, and that your reimbursements can resume. Some reimbursements may be cleared, but agencies may prioritize backlog.
  • Review milestones and deliverables: Identify any tasks paused or delayed and map them to your internal program plan. Update dependencies.
  • Communicate with internal stakeholders: Let leadership, project teams and finance know of any changes, potential catch-up work, and budget impacts.
• Resuming work and catching up
  • Budget & cash-flow review: If reimbursements were delayed, review whether internal bridge funds were used and whether any cost overruns occurred.
  • Project schedule adjustment: If a submission, review, contract start or enrollment period was delayed, update your Gantt or milestone chart accordingly.
  • Adjust risk register: Add an item for “federal shutdown / funding lapse” as a defined risk with mitigation (even if the event has passed). Use this as a learning moment.
  • Re-establish oversight & compliance rhythms: If certain compliance functions were suspended (audit readiness, progress reporting), get them back in motion.
  • Agency relationship building: Use your contact with the agency to reset expectations, confirm next steps, and understand any new backlog or prioritization. Some agencies may prioritize older applications or awards first.
• Capturing lessons and maintaining resilience
  • Post-mortem review: Host a short internal review of how your organization handled the shutdown — what went well, what didn’t, what you would do differently next time.
  • Update internal processes: Consider drafting a “shutdown playbook” for your biotech team — how to pause work, communicate internally, manage cash-flow, engage agency contacts.
  • Scenario-planning: Because shutdowns are recurrent risks, include it in your risk planning for future grant cycles or contracts.
  • Communicate with partners & stakeholders: Update investors, collaborators, and customers that you have resumed full operations and any schedule adjustments.
    

Why this matters for biotech

For biotech companies — especially those developing therapeutic platforms, biologics or advanced modalities where federal funding, federal lab collaborations or regulatory agency interactions are central — a shutdown isn’t just a short-term interruption. It can:

• Delay access to new funding rounds, which can slow the next discovery or clinical phase.
• Disrupt contract or collaboration milestones tied to federal agencies, delaying timelines.
• Impose cash-flow stress if reimbursements are delayed and internal reserves aren’t adequate.
• Create uncertainty in regulatory or cooperative arrangements, which can impair strategic planning.

By proactively planning for shutdown risk, you strengthen your funding resilience, protect program momentum and reinforce credibility with stakeholders (partners, investors, regulators). 

How Harmony Biotech Consulting Can Help

When federal funding and agency interaction are a part of your biotech strategy, our consulting services bring practical guidance:

• Federal funding readiness: We advise biotech firms on how to structure programs and budget for potential disruptions (e.g., shutdowns, CRs, delays) and protect cash-flow.
  
• Contract & grant lifecycle support: We provide project management for government contracts and programs including BARDA, DoD, NIH and others. We assist in tracking dependencies on federal agency actions, grant/contract milestones, and building contingency plans when appropriations uncertainty looms. We also write proposals for new grants quickly when they become available.
  
• Post-shutdown ramp-Up strategy: If you’ve been impacted by a shutdown, we help you resume operations, re-baseline schedules, manage audit readiness and stakeholder communication.
  
• Risk & compliance framework: We build risk registers, scenario-planning matrices and internal playbooks for shutdown-related interruptions, so your team remains resilient and responsive.

Federal government shutdowns pose real, often under-appreciated risks to biotech funding, grant operations, regulatory interactions and project momentum. Understanding which funding streams pause, how processes are impacted and what it takes to ramp back up equips organizations to protect their timelines, budgets and strategic integrity.

At Harmony Biotech, we believe that planning for these contingencies isn’t an afterthought — it’s a core component of operational readiness. With a proactive approach, you can ensure that even during periods of funding uncertainty, your breakthrough science stays on track.